A5064201088- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Histone Deacetylase Inhibitors Research
- Epigenetics and DNA Methylation
- Cancer Immunotherapy and Biomarkers
- Multiple Myeloma Research and Treatments
- CAR-T cell therapy research
- Hematopoietic Stem Cell Transplantation
- Lymphoma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Acute Lymphoblastic Leukemia research
- Eosinophilic Disorders and Syndromes
- Neutropenia and Cancer Infections
- Immune Cell Function and Interaction
- Cancer Genomics and Diagnostics
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Retinoids in leukemia and cellular processes
- Protein Degradation and Inhibitors
- Immunodeficiency and Autoimmune Disorders
- Cancer Treatment and Pharmacology
- Beetle Biology and Toxicology Studies
- Organ Transplantation Techniques and Outcomes
- Pneumocystis jirovecii pneumonia detection and treatment
Fox Chase Cancer Center
2013-2024
Temple University Hospital
2015-2024
Cancer Institute (WIA)
2023
Novant Health
2023
Temple University Health System
2017-2019
Temple University
2011-2019
Juno Therapeutics (Germany)
2018
Novartis (Germany)
2018
City of Hope
2018
University of Pittsburgh
2018
Acute myeloid leukemia (AML) is the most common form of acute among adults and accounts for largest number annual deaths due to leukemias in United States. This portion NCCN Guidelines AML focuses on management provides recommendations workup, diagnostic evaluation, treatment options younger (age <60 years) older ≥60 adult patients.
The NCCN Guidelines for Chronic Myeloid Leukemia (CML) provide recommendations the management of chronic-phase and advanced-phase CML in adult patients. median age disease onset is 67 years. However, because occurs all groups, clinical care teams should be prepared to address issues relating fertility pregnancy with patients who are reproductive at time diagnosis. relatively rare children there no evidence-based pediatric population. These Insights discuss special considerations during
The 2014 NCCN Clinical Practice Guidelines in Oncology for Chronic Myelogenous Leukemia recommend quantitative reverse-transcription polymerase chain reaction (QPCR) standardized to International Scale (IS) as the preferred method monitoring molecular response tyrosine kinase inhibitor (TKI) therapy. A BCR-ABL1 transcript level of 10% or less is now included milestone at 3 and 6 months. Change therapy an alternate TKI recommended patients with levels greater than months after primary...
Myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are a group of heterogeneous disorders the hematopoietic system collectively known as Philadelphia chromosome–negative myeloproliferative neoplasms (MPNs). The diagnosis management patients with MPNs have evolved since identification mutations that activate JAK pathway (JAK2, CALR, MPL mutations) development targeted therapies has resulted in significant improvements disease-related symptoms quality life. This...
Chronic myelogenous leukemia (CML) is usually diagnosed in the chronic phase. Untreated phase CML will eventually progress to advanced (accelerated or blast phase) CML. Tyrosine kinase inhibitors (TKIs) have been shown induce favorable response rates patients with accelerated and The addition of TKIs chemotherapy has also associated improved outcomes Allogeneic hematopoietic stem cell transplant remains a potentially curative option for CML, although treatment course be beneficial as bridge...
BACKGROUND Outcomes for patients with relapsed or refractory acute myeloid leukemia (AML) are poor. Guadecitabine, a next‐generation hypomethylating agent, could be useful in treating such patients. METHODS In this multicenter, open‐label, phase 2 dose‐expansion study, AML from 10 North American medical centers were first randomized (1:1) to receive subcutaneous guadecitabine at 60 90 mg/m on 5 consecutive days each 28‐day cycle (5‐day regimen). Subsequently, another cohort was treated...
This phase 3 study evaluated the efficacy and safety of new hypomethylating agent guadecitabine (n = 408) vs a preselected treatment choice (TC; n 407) azacitidine, decitabine, or low-dose cytarabine in patients with acute myeloid leukemia unfit to receive intensive induction chemotherapy. Half (50%) had poor Eastern Cooperative Oncology Group Performance Status (2-3). The coprimary end points were complete remission (19% 17% for TC, respectively [stratified P .48]) overall survival (median...
Abstract Purpose: We hypothesized that resistance to hypomethylating agents (HMA) among patients with myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) would be overcome by combining a programmed death-ligand 1 antibody an HMA. Patients Methods: conducted Phase I/II, multicenter clinical trial for MDS not achieving International Working Group response after at least 4 cycles of HMA (“refractory”) or progressing (“relapsed”) 3+ higher risk the revised Prognostic...
Graft versus host disease (GVHD) is a common complication of allogeneic transplant. Acute GVHD primarily affects the skin, liver, and GI tract generally within first 100 days after following an transplant occurs as result donor T-cell recognition alloantigens. In contrast, patients undergoing ASCT are not subjected to genetic disparity that with transplant, in principal, should develop this proinflammatory response. A clinical syndrome, however, has been described autologous shares same...
Guadecitabine is a novel DNA methyltransferase (DNMT) inhibitor with improved pharmacokinetics and clinical activity in subset of patients relapsed/refractory acute myeloid leukemia (r/r AML), but identification this remains difficult. To search for biomarkers response, we measured genome-wide methylation, mutations 54 genes, expression panel 7 genes pre-treatment samples from 128 treated at therapeutic doses phase I/II study. Response rate to guadecitabine was 17% (2 complete remission...
Patients with relapsed or refractory (R/R) cancers have a poor prognosis and limited treatment options. The recent approval of 2 chimeric antigen receptor (CAR) autologous T-cell products for R/R B-cell acute lymphoblastic leukemia non-Hodgkin's lymphoma is setting the stage what possible in other diseases. However, there are important factors that must be considered, including patient selection, toxicity management, costs associated CAR therapy. To begin to address these issues, NCCN...
Src family kinases (SFKs) are hyperactivated in acute myeloid leukemia (AML). SFKs impede the retinoic acid receptor, and SFK inhibitors enhance all-trans (ATRA)-mediated cellular differentiation AML cell lines primary blasts. To translate these findings into clinic, we undertook a phase-I dose-escalation study of combination inhibitor dasatinib ATRA patients with high-risk neoplasms. Nine subjects were enrolled: six received 70 mg plus 45 mg/m2 daily, three 100 daily for 28 days. Headache...